Immunis, Inc. obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group. Immunis licensed development and commercial rights to the Japan-commercially-approved drug called TRK-820, an opioid receptor agonist developed initially for the treatment of pruritus or sever itching. Immunis?

formulation of TRK-820 shows pre-clinical benefits for sarcopenia, and may serve as a promising pharmaceutical complement to IMMUNA, Immunis? human-derived regenerative biologic published to reverse age-related muscle loss, promote muscle growth and function, and enhance metabolism. Immunis is currently conducting independent validations to measure the efficacy of TRK-820 in reversing sarcopenia and will apply for a Phase 2 clinical trial to assess efficacy in humans.

The advantages of adding TRK-820 to Immunis? portfolio are that it can be taken orally and that it offers a different mechanism of action than IMMUNA to potentially enhance muscle regeneration in humans. Both Immunis and Toray operate with the mission of advancing human healthcare and enhancing quality of life.

Immunis is excited by the opportunities that this partnership can offer, and they hope to successfully address sarcopenia as a united front.